Skip to main content

Table 5 Short-term efficacy of monotherapy after multi-line chemotherapy

From: Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China

Short-term efficacyNumber of patients (Percent)
Complete response (CR)0 (0)
Partial response (PR)0 (0)
Stable disease (SD)1 (33.3)
Progressive disease (PD)2 (66.7)